G

Glenmark Life Sciences Ltd
NSE:GLS

Watchlist Manager
Glenmark Life Sciences Ltd
NSE:GLS
Watchlist
Price: 1 045.65 INR -3.19% Market Closed
Market Cap: 128.1B INR
Have any thoughts about
Glenmark Life Sciences Ltd?
Write Note

Glenmark Life Sciences Ltd
Total Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Glenmark Life Sciences Ltd
Total Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Equity CAGR 3Y CAGR 5Y CAGR 10Y
G
Glenmark Life Sciences Ltd
NSE:GLS
Total Equity
â‚ą23.3B
CAGR 3-Years
46%
CAGR 5-Years
93%
CAGR 10-Years
N/A
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
Total Equity
â‚ą282.5B
CAGR 3-Years
17%
CAGR 5-Years
15%
CAGR 10-Years
N/A
Cipla Ltd
NSE:CIPLA
Total Equity
â‚ą283.6B
CAGR 3-Years
13%
CAGR 5-Years
13%
CAGR 10-Years
10%
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
Total Equity
â‚ą691.1B
CAGR 3-Years
12%
CAGR 5-Years
10%
CAGR 10-Years
12%
T
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
Total Equity
â‚ą75B
CAGR 3-Years
6%
CAGR 5-Years
8%
CAGR 10-Years
12%
M
Mankind Pharma Ltd
NSE:MANKIND
Total Equity
â‚ą93.6B
CAGR 3-Years
26%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Glenmark Life Sciences Ltd
Glance View

Market Cap
128.1B INR
Industry
Pharmaceuticals

Glenmark Life Sciences Ltd. engages in the development and manufacture of non-commoditized active pharmaceutical ingredients. The company is headquartered in Solapur, Maharashtra. The company went IPO on 2021-08-06. The Company’s product portfolio comprises of various therapeutic segments, which include cardiovascular (CVS) disease, central nervous system (CNS) disorders, diabetes, gastrointestinal health, oncology, pain management and anti-infectives. Its products include Adapalene, Alogliptin Benzoate, Amiodarone HCl, Esomeprazole Sodium, Eszopiclone, Etoricoxib, Omeprazole, Oxcarbazepine, Zolpidem Tartrate, Zonisamide and Voriconazole. The Company’s products also include Vildagliptin, Aprepitant, Bosentan, Cilostazol, Deferasirox, Fluconazole, Ivacaftor, Pirfenidone, Riluzole, Sucralfate, Ticagrelor, Telmisartan and Umifenovir. The Company’s research and development facilities are located at Mahape, Ankleshwar and Dahej in India and manufacturing facilities are located at Ankleshwar, Dahej, Mohol and Kurkumbh.

GLS Intrinsic Value
715.71 INR
Overvaluation 32%
Intrinsic Value
Price
G

See Also

What is Glenmark Life Sciences Ltd's Total Equity?
Total Equity
23.3B INR

Based on the financial report for Mar 31, 2024, Glenmark Life Sciences Ltd's Total Equity amounts to 23.3B INR.

What is Glenmark Life Sciences Ltd's Total Equity growth rate?
Total Equity CAGR 5Y
93%

Over the last year, the Total Equity growth was 9%. The average annual Total Equity growth rates for Glenmark Life Sciences Ltd have been 46% over the past three years , 93% over the past five years .

Back to Top